Operational Summary

for the Year Ended March 31, 2011

May 11, 2011 Mitsubishi Chemical Holdings Corporation

Table of Contents

Consolidated Financial Statements for FY2010
Statements of Operations
Net Sales by Business Segment
Operating Income by Business Segment
Operating Analysis (FY2009 vs. FY2010)
Extraordinary Gain (Loss)
Cash Flows
Balance Sheets
Statement of Changes in Net Assets
Statements of Comprehensive Income

Pg No.	Consolidated Financial Statements Forecasts for FY2011	Pg No.
4	Impact of the Earthquake	13
5	Statements of Operations	14
6	Net Sales by Business Segment	15
7	Operating Income by Business Segment	16
8	Operating Analysis (FY2010 vs. FY2011)	17
9	Operating Analysis (1H of FY2011 vs. 2H of FY2011)	18
10	Cash Flows and Other Numerical Targets	19
11	Cash Dividends	20

12

References

Scope of consolidation and Overseas Sales and Operating Income	22
Major Subsidiaries	23
Trend of Financial Position	24
Capital Expenditure, Depreciation & Amortization, R&D Expenses, Total Assets, and Number of Employees by Business Segment	25
Operating Income by Business Segment (1Q and 2Q of FY2011 Forecast)	26

FY2011:	April 1, 2011 - March 31, 2012 1st Quarter ("1Q") of FY2011 : April 1, 2011 - June 30, 2011 2nd Quarter ("2Q") of FY2011 : Julyl 1, 2011 - September 30, 2011 2nd Half ("2H") of FY2011 : October 1, 2011 - March 31, 2012	}	1st Half ("1H") of FY2011
FY2010:	April 1, 2010 - March 31, 2011 1st Quarter ("1Q") of FY2010 : April 1, 2010 - June 30, 2010 2nd Quarter ("2Q") of FY2010 : Julyl 1, 2010 - September 30, 2010 2nd Half ("2H") of FY2010 : October 1, 2010 - March 31, 2011	}	1st Half ("1H") of FY2010
FY2009:	April 1, 2009 - March 31, 2010		
Previous Forecast:	Company's forecasts disclosed on November 2, 2010 for FY2010		
MCHC: MCC:	Mitsubishi Chemical Holdings Corporation Mitsubishi Chemical Corporation		

- MTPC:Mitsubishi Tanabe Pharma CorporationMPI:Mitsubishi Plastics, Inc.
- MRC: Mitsubishi Rayon Co., Ltd.
- **NSCI:** The Nippon Synthetic Chemical Industory Co., Ltd.

Consolidated Statements of Operations

Exchange rate for translation of foreign statements (¥/US\$) Naphtha price (¥/kl)	91 46.200	84 48.800	87 47.500	94 41,200		<u>90</u> 45.600	
	40,200	40,000	47,500		(Billions of Yen)		(Billions of Yen)
			FY2010	FY2009		FY2010	
	1H	2H	Actual	Actual	Change	(Previous Forecast)	Change
Net sales	1,564.7	1,602.1	3,166.8	2,515.1	651.7	3,190.0	(23.2)
Operating income	111.4	115.1	226.5	66.3	160.2	203.0	23.5
Income (expenses) on financing activities	(4.8)	(4.1)	(8.9)	(6.4)	(2.5)	(10.0)	1.1
[Dividend income included in above]	[2.3]	[2.7]	[5.0]	[4.2]	[0.8]	[5.0]	[0.0]
Equity in Earnings of non-consolidated subsidiaries and affiliates	6.2	8.9	15.1	6.5	8.6	16.0	(0.9)
Other non-operating income (expenses)	(6.4)	(2.4)	(8.8)	(7.4)	(1.4)	(13.0)	4.2
Ordinary income	106.4	117.5	223.9	59.0	164.9	196.0	27.9
Extraordinary gain	3.5	3.2	6.7	31.7	(25.0)	(33.0)	(21.3)
Extraordinary loss	(16.1)	(44.9)	(61.0)	(47.4)	(13.6)	(55.0)	(21.3)
Income before income taxes and minority interests	93.8	75.8	169.6	43.3	126.3	163.0	6.6
Current and deferred income taxes	(28.0)	(19.0)	(47.0)	(10.5)	(36.5)	(51.0)	4.0
Minority interests in consolidated subsidiaries	(21.9)	(17.1)	(39.0)	(20.0)	(19.0)	(37.0)	(2.0)
Net income	43.9	39.7	83.6	12.8	70.8	75.0	8.6
Comprehensive income attributable to :			86.7	37.5	49.2		
-							
Shareholders of owners of the parent			51.6 25.4	16.3	35.3		
Minority interests	\sim		35.1	21.2	13.9		

Consolidated Net Sales by Business Segment

aphtha price (¥/kl)	46,200	48,800	47,500	41,200	6,300		45,600	
					(Billions of Yen)	(Reference)	(Reference)	(Billions of Ye
	1H	2H	FY2010 Actual	FY2009 Actual	Change	Change with adjustments**	(Previous Forecast)	Change
Total	1,564.7	1,602.1	3,166.8	2,515.1	651.7	193.1	3,190.0	(23.2
Electronics Applications	80.6	71.8	152.4	167.3	(14.9)	(14.9)	163.0	(10.
Designed Materials	326.8	330.7	657.5	436.8	220.7	17.3	678.0	(20.
Functional Products* Performance Chemicals*	220.6 106.2	227.4 103.3	448.0 209.5	301.4 135.4	146.6 74.1	15.0 2.3	460.0 218.0	(12. (8.
Health Care	251.8	253.2	505.0	504.4	0.6	0.6	502.0	3.
Pharmaceuticals* Diagnostics, Clinical Testing and API*	204.6 47.2	204.9 48.3	409.5 95.5	404.6 99.8	4.9 (4.3)	4.9 (4.3)	401.0 101.0	8 (5
Chemicals	435.3	460.1	895.4	785.7	109.7	89.5	889.0	6.
Petrochemicals* Carbon*	318.8 116.5	337.2 122.9	656.0 239.4	566.9 218.8	89.1 20.6	68.9 20.6	647.0 242.0	9. (2.
Polymers	362.7	368.5	731.2	479.1	252.1	66.7	731.0	0.
Polyolefins and Advanced Polymers* MMA Monomers and Polymers*	230.5 132.2	230.9 137.6	461.4 269.8	479.1 -	<mark>(17.7)</mark> 269.8	66.7 -	467.0 264.0	<mark>(5</mark> 5
Others	107.5	117.8	225.3	141.8	83.5	33.9	227.0	(1.

Notes:

Some businesses and subsidiaries were reclassified in response to adoption of new accounting standards, and therefore the results of FY2009 were adjusted accordingly.

*Approximation for reference purpose only

**For better comparison, FY2010 results were adjusted for:

newly consolidated businesses whose results were not (fully) included in the results of FY2009,

certain businesses divested in FY2009,

and certain businesses whose results of FY2009 included additional three months due to change in their accounting periods.

Consolidated Operating Income by Business Segment

					(Billions of Yen)		(Reference)	(Billions of Yen
	1H	2H	FY2010 Actual	FY2009 Actual	Change	Change with adjustments**	FY2010 (Previous	Change
Total	111.4	115.1	226.5	66.3	160.2	151.2	Forecast) 203.0	23.5
Electronics Applications	3.2	(2.2)	1.0	(1.4)	2.4	2.4	4.0	(3.0
Designed Materials	20.8	15.7	36.5	13.3	23.2	25.2	38.0	(1.5
Functional Products* Performance Chemicals*	8.1 12.7	7.1 8.6	15.2 21.3	2.8 10.5	12.4 10.8	22.9 2.3	15.0 23.0	0.2
Health Care	44.6	40.5	85.1	71.0	14.1	14.1	77.0	8.1
Pharmaceuticals* Diagnostics, Clinical Testing and API*	42.1 2.5	39.5 1.0	81.6 3.5	66.4 4.6	15.2 (1.1)	15.2 (1.1)	72.0 5.0	9.6 (1.5
Chemicals	21.9	31.1	53.0	6.9	46.1	46.0	44.0	9.0
Petrochemicals* Carbon*	8.7 13.2	22.6 8.5	31.3 21.7	<mark>(2.0)</mark> 8.9	33.3 12.8	33.2 12.8	23.0 21.0	8.3 0.7
Polymers	24.3	30.7	55.0	(22.5)	77.5	67.8	45.0	10.0
Polyolefins and Advanced Polymers* MMA Monomers and Polymers*	11.2 13.1	7.0 23.7	18.2 36.8	(22.5)	40.7 36.8	40.7 27.1	16.0 29.0	2.2
Others	0.6	3.9	4.5	6.3	(1.8)	(3.0)	3.0	1.5
Corporate	(4.0)	(4.6)	(8.6)	(7.3)	(1.3)	(1.3)	(8.0)	(0.6
Impact of the earthquake	;	1.7	1.7			nventory valuation gain/los	FY2010	0 FY2009 Chang

Notes:


Some businesses and subsidiaries were reclassified in response to adoption of new accounting standards, and therefore the results of FY2009 were adjusted accordingly.

*Approximation for reference purpose only

**For better comparison, FY2009 results were adjusted for newly consolidated businesses whose results were not (fully) included in the results of FY2009.

Inventory valuation gain/loss	FY2010 Actual	FY2009 Actual	Change
Chemicals (Petrochemicals)	4.7	8.8	(4.1)
Chemicals (Carbon)	3.8	(3.3)	7.1
Polymers (Polyolefins and Advanced Polymers	5.6	(16.1)	21.7
Total	14.1	(10.6)	24.7

Operating Analysis (FY2009 vs. FY2010)



Consolidated Extraordinary Gain (Loss)

				(Billions of Yen)
		FY2010	FY2009	
	4Q	Actual	Actual	Change
Total	(38.5)	(54.3)	(15.7)	(38.6)
Extraordinary gain	2.1	6.7	31.7	(25.0)
Gain related to acquisitions and divestments	0.2	1.3	25.9	(24.6)
Others	1.9	5.4	5.8	(0.4)
Gain on sales of investment securuties Others	0.1 1.8	2.0 3.4	2.1 3.7	(0.1) (0.3)
Extraordinary loss	(40.6)	(61.0)	(47.4)	(13.6)
Losses on the Great East Japan Earthquake	(22.5)	(22.5)	-	(22.5)
Business structure improvement expenses	(5.5)	(9.6)	(17.8)	8.2
Others	(12.6)	(28.9)	(29.6)	0.7
Loss on valuation of investment securities	(4.7)	(10.8)	(0.6)	(10.2)
Eenvironmental expenses Loss on adjustment for changes of accounting standard	-	(1.6)	-	(1.6)
for asset retirement obligations	-	(1.5)	-	(1.5)
Others	(7.9)	(15.0)	(29.0)	14.0

Losses on the Great East Japan Earthquake

Details:

Expenses to fix property (14.4) Fixed costs during the suspension of production facilities (3.5) Lost or damaged inventories (1.7) Others (2.9)

Consolidated Cash Flows

	Based on s of cash		invest	g financial ments in hands	
	(Billions of Y				
	FY2010 Actual	FY2009 Actual	FY2010 Actual With adjustment 0.8 billion yen for financial investment	FY2009 Actual With adjustment 54.3 billion yen for financial investment	
Net cash provided by operating activities	288.9	116.1	288.9	116.1	
Income before income taxes	169.6	43.3	169.6	43.3	
Depreciation	148.7	129.6	148.7	129.6	
Amortization of goodwill	12.1	8.3	12.1	8.3	
Change in operating receivables/payables	7.7	(72.5)	7.7	(72.5)	
Change in Inventories	(17.4)	63.4	(17.4)	63.4	
Others	(31.8)	(56.0)	(31.8)	(56.0)	
Net cash used in investment activities	(101.1)	(327.0)	(100.3)	(272.7)	
Capital expenditure	(115.4)	(120.5)	(115.4)	(120.5)	
Investment and loans receivables, etc.	14.3	(206.5)	15.1	(152.2)	
Free cash flow	187.8	(210.9)	188.6	(156.6)	
Net cash provided by (used in) financing activities	(149.5)	94.4			
Interest bearing debt	(126.4)	114.6			
Dividends, etc.	(23.1)	(20.2)			
Increase (decrease) in cash and cash equivalents	38.3	(116.5)			
Balance of cash and cash equivalents	143.7	112.6			

Consolidated Balance Sheets

			(Billions of Yen)
	Mar. 31, 2011 Actual	Mar. 31, 2010 Actual	Change
Cash and deposits	130.2	119.1	11.1
Inventories	485.1	474.7	10.4
Trade receivables	597.2	595.7	1.5
Others	184.2	179.6	4.6
Current assets	1,396.7	1,369.1	27.6
Fixed assets	1,160.4	1,209.8	(49.4)
Goodwill	154.8	171.7	(16.9)
Investment and Others	582.1	604.5	(22.4)
Fixed assets	1,897.3	1,986.0	(88.7)
Total assets	3,294.0	3,355.1	(61.1)

	(Billions of Yen)					
	Mar. 31, 2011 Actual	Mar. 31, 2010 Actual	Change			
Interest-bearing debts	1,304.6	1,454.1	(149.5)			
Trade payables	378.4	370.8	7.6			
Others	497.0	497.3	(0.3)			
Liabilities	2,180.0	2,322.2	(142.2)			
Shareholders' equity	808.8	693.9	114.9			
Valuation and translation adjustments	(50.5)	(20.3)	(30.2)			
Minorities interests, etc.	355.7	359.3	(3.6)			
Net assets	1,114.0	1,032.9	81.1			

Total liabilities and net assets	3,294.0	3,355.1	(61.1)
----------------------------------	---------	---------	--------

Interest-bearing debts (incl. notes)	1,304.6	1,454.1	(149.5)
Debt-equity ratio	1.72	2.16	(0.44)
Net interest-bearing debts (*1)	1,008.7	1,190.1	(181.4)
Net debt-equity ratio	1.33	1.77	(0.44)
Shareholders' equity (*2)	758.3	673.6	84.7
Shareholders' equity ratio	23.0%	20.0%	3.0%

*1. Net interest-bearing debts (1,008.7 billion yen)

= interest bearing debts, including discounted notes (1,304.6 billion yen)

- {cash and cash equivalents (143.7 billion yen + financial investments of cash-in-hands (152.2 billion yen)}

*2. Represents net assets encluding share subscription rights and minority interests

Consolidated Statement of Changes in Net Assets

						illions of Yen)								
	Common stock	Additional paid-in capital	Retained earnings	Treasury stock at cost	Total shareholders' equity	Net unrealized holding gain (loss) on other securities	Loss on deferred hedges	Land revaluation surplus	Foreign currency translation adjustments	Unfunded retirement benefit obligation with respect to a foreign subsidiary	Total Valuation and translation adjustments	Warrants	Minority interests in consolidated subsidiaries	Total net assets
Balance as of Mar. 31, 2010	50.0	303.3	379.4	(38.8)	693.9	11.8	(0.1)	1.4	(30.1)	(3.2)	(20.3)	0.7	358.6	1,032.9
Cash dividends			(12.4)		(12.4)						-			(12.4)
Net income			83.6		83.6						-			83.6
Purchase of treasury stock				(0.2)	(0.2)						-			(0.2)
Disposal of treasury stock		14.3		28.2	42.5						-			42.5
Increase due to merger of non-consolidated subsidiaries by an equity- method affiliate			0.1		0.1						-			0.1
Change in scope of consolidation			0.0		0.0						-			0.0
Change in scope of equity method			(0.0)		(0.0)						-			(0.0)
Effect on changes of currency of a subsidiary			1.2		1.2				1.8		1.8		1.6	4.6
Net change in items other than those in shareholders' equity						(6.5)	(0.6)	-	(24.0)	(0.8)	(32.0)	0.0	(5.1)	(37.1)
Net changes of items during the period	-	14.3	72.6	28.0	114.9	(6.5)	(0.6)	-	(22.3)	(0.8)	(30.2)	0.0	(3.6)	81.1
Balance as of Mar. 31, 2011	50.0	317.6	451.9	(10.8)	808.8	5.2	(0.7)	1.4	(52.4)	(4.0)	(50.5)	0.7	355.1	1,114.0

(Billions of Yen)

Consolidated Statements of Comprehensive Income

Exchange rate for translation of foreign statements (¥/US\$)	81.5	92.1	(10.6)
Exchange rate for translation of foreign statements (¥/€)	107.9	132.0	(24.1)
NIKKEI 225 Index (Yen)	9,755	11,090	(1,335)

		(Bill	ions of Yen)
	FY2010 Actual	FY2009 Actual	Change
Net income	83.6	12.8	70.8
Minority interests in consolidated subsidiaries	39.0	20.0	19.0
Income before minority interests	122.6	32.8	89.8
Other comprehensive income (expenses):			
Net unrealized holding gain (loss) on other securities	(6.5)	0.7	(7.2)
Gain (loss) on deferred hedges	(1.0)	0.5	(1.5)
Foreign currency translation adjustments	(25.0)	1.9	(26.9)
Unfunded retirement benefit obligation with respect to a foreign subsidiary	(0.8)	1.0	(1.8)
Share of other comprehensive income of affiliates accounted for using equity method	(2.6)	0.6	(3.2)
Other comprehensive income (expenses), net	(35.9)	4.7	(40.6)
Total comprehensive income	86.7	37.5	49.2
Total comprehensive income attributable to :			
Shareholders of owners of the parent	51.6	16.3	35.3
Minority interests	35.1	21.2	13.9

12



Impact of the Earthquake

Estimated 40.0 billion yen as the impacts of the earthquake to include in FY2011 forecast.

			(Billions of Yen)
	FY2011 Forecast	FY2010 Actual	Total
Impacts of the eathquake	(40.0)	(20.8)	(60.8)
Decrease in production/sales	(40.0)	(1.8)	(41.8)
Expenses to fix property	-	(14.4)	(14.4)
Lost or damaged inventories	-	(1.7)	(1.7)
others	-	(2.9)	(2.9)

Effect on operating income	(30.0)	1.7	(28.3)
Extraordinary loss	(10.0)	(22.5)	(32.5)

Also, included 9.0 billion yen insurance in FY2011 forecast.

Consolidated Statements of Operations (FY2011 Forecast)




Assumption for Exchange rate (¥/US\$)	85	85	85	-	-	-
Naphtha price (¥/kl)	62,000	62,000	62,000	46,200	48,800	47,500

(Billions of Yen)

	1H Forecast	2H Forecast	FY2011 Forecast	1H Actual	2H Actual	FY2010 Actual	Change
Net sales	1,680.0	1,900.0	3,580.0	1,564.7	1,602.1	3,166.8	413.2
Operating income	81.0	125.0	206.0	111.4	115.1	226.5	(20.5)
Income (expenses) on financing activities [Dividend income included in above] Equity in Earnings of non-consolidated subsidiaries and affiliates Other non-operating income (expenses)	(4.0) [3.1] 9.0 (7.0)	(5.0) [1.9] 8.0 (2.0)	[5.0] 17.0	[2.3] 6.2			(0.1) [0.0] 1.9 (0.2)
Ordinary income	79.0	126.0	205.0	106.4	117.5	223.9	(18.9)
Extraordinary gain Extraordinary loss	2.0 (16.0)	7.0 (16.0)	9.0 (32.0)	3.5 (16.1)	3.2 (44.9)	6.7 (61.0)	2.3 29.0
Income before income taxes and minority interests	65.0	117.0	182.0	93.8	75.8	169.6	12.4
Current and deferred income taxes Minority interests in consolidated subsidiaries	(22.0) (17.0)	(35.0) (28.0)	· · · ·	• •	• •	· · · ·	(10.0) (6.0)
Net income	26.0	54.0	80.0	43.9	39.7	83.6	(3.6)

Consolidated Net Sales by Business Segment (FY2011 Forecast)



* Approximation for reference purpose only

Consolidated Operating Income by Business Segment (FY2011 Forecast) Forecast

							(Billions of Yer
	1H Forecast	2H Forecast	FY2011 Forecast	1H Actual	2H Actual	FY2010 Actual	Change
Total	81.0	125.0	206.0	111.4	115.1	226.5	(20.5
Electronics Applications	0.0	4.0	4.0	3.2	(2.2)	1.0	3.0
Designed Materials	17.0	19.0	36.0	20.8	15.7	36.5	(0.5
Functional Products (*) Performance Chemicals (*)	7.0	8.0 11.0	15.0 21.0	8.1 12.7	7.1 8.6	15.2 21.3	(0. (0.
Health Care	27.0	45.0	72.0	44.6	40.5	85.1	(13.1
Pharmaceuticals (*) Diagnostics, Clinical Testing and API (*)	25.0 2.0	42.0 3.0	67.0 5.0	42.1 2.5	39.5 1.0	81.6 3.5	(14.
Chemicals	20.0	30.0	50.0	21.9	31.1	53.0	(3.0
Petrochemicals (*) Carbon (*)	12.0 8.0	21.0 9.0	33.0 17.0	8.7 13.2	22.6 8.5	31.3 21.7	1. (4.
Polymers	20.0	28.0	48.0	24.3	30.7	55.0	(7.0
Polyolefins and Advanced Polymers (*) MMA Monomers and Polymers (*)	1.0 19.0	11.0 17.0	12.0 36.0	11.2 13.1	7.0 23.7	18.2 36.8	(6. (0.
Others	1.0	3.0	4.0	0.6	3.9	4.5	(0.
Corporate	(4.0)	(4.0)	(8.0)	(4.0)	(4.6)	(8.6)	0.0


* Approximation for reference purpose only

Impact of the earthquake	(24.2)	(5.8)	(30.0)	-	1.7	1.7	(31.7)
Operating income exclud. impact of the earthquake	105.2	130.8	236.0	111.4	113.4	224.8	11.2
Operating income exclud. impact of the earthquake and results of "Pharmaceuticals"	74.2	87.8	162.0	69.3	77.9	147.2	14.8


Inventory valuation gain/loss	FY2011 Forecast	FY2010 Actual	Change
Chemicals (Petrochemicals)	3.4	4.7	(1.3)
Chemicals (Carbon)	0.5	3.8	(3.3)
Polymers(Polyolefins and Advanced Polymers)	9.9	5.6	4.3
Total	13.8	14.1	(0.3)

16

Operating Analysis (FY2010 Actual vs. FY2011 Forecast)



Operating Analysis (1H of FY2011 vs. 2H of FY2011 Forecast)



Consolidated Cash Flows and Other Numerical Targets

		(Billions of Yen)
	FY2011	FY2010
	Target	Actual
	Excluding financial	Excluding financial
	investments of cash in hands	investments of cash in hands
Net cash provided by operating activities	236.0	288.9
Income before income taxes	182.0	169.6
Depreciation	152.0	148.7
Amortization of goodwill	12.0	12.1
Change in working capital	(25.0)	(9.7)
Others	(85.0)	(31.8)
Net cash used in investment activities	(126.0)	(100.3)
Capital expenditure	(146.0)	(115.4)
Investment and loans receivables, etc.	20.0	15.1
Free cash flow	110.0	188.6

	March 31, 2012 Target	March 31, 2011 Actual	Change
Net interest-bearing debts	930.0	1,008.7	(78.7)
Net debt-equity ratio	less than 1.15	1.33	(0.18)
Shareholders' equity	823.0	758.3	64.7
EBITDA*1	370.0	387.3	(17.3)
Net income	80.0	83.6	(3.6)
Net profit per share (Yen)	¥54.26	¥58.72	(¥4.46)

*1 EBITDA = Operating income + Depreciation + Amortization of goodwill



Cash Dividends

		FY2011 Forecast	FY2010 Actual	FY2009 Actual	FY2008 Actual
	1st Half	5	5	4	8
Cash dividends per share (Yen)	Year end	5	5	4	4
	Total	10	10	8	12
	1st Half		6.9	5.5	11.0
Total of cash dividends (Billions of yen)	Year end		7.4	5.5	5.5
	Total		14.3	11.0	16.5
Net profit per share (Yen)	Year end	¥54.26	¥58.72	¥9.32	(¥48.81)
Dividend pay out ratio (Consolidated)	-	18.4%	17.0%	85.8%	-

References

Scope of Consolidation and Overseas Sales and Operating Income

(Number of affiliates)

Scope of consolidation	FY2010	FY2009	FY2008	FY2007
Total	411	421	240	260
Consolidated subsidiaries	341	345	177	189
Japan	127	129	95	106
Overseas	214	216	82	83
Affiliates accounted for by the equity method	70	76	63	71

Net sales and operating income by geographic area based

on location of consolidated subsidiaries

(Billions of Yen)

	-		(•	
Japan	2,436.8	2,116.4	2,477.4	2,420.6
Overseas	730.0	398.7	431.6	509.2
Net sales	3,166.8	2,515.1	2,909.0	2,929.8
Japan	153.2	44.9	11.7	126.8
Overseas	73.3	21.4	(3.5)	(1.8)
Operating income	226.5	66.3	8.2	125.0

Overseas sales			(E	Billions of Yen)
Overseas sales	1,087.6	637.2	668.1	795.4
	34.3%	25.3%	22.9%	27.1%

Major Subsidiaries

	Net Sales			Operating Income			
Company					(E	Billions of Yen)	
(Consolidated)	FY2010	FY2009	Change	FY2010	FY2009	Change	
МСС	2,019.6	1,874.8	144.8	88.1	(0.8)	88.9	
МТРС	409.5	404.7	4.8	76.6	61.5	15.1	
MPI	382.0	313.2	68.8	16.6	1.6	15.0	
MRC	478.4	[365.0]*	478.4	41.0	[5.4]*	41.0	
Adjustments**	(122.7)	(77.6)	(45.1)	4.2	4.0	0.2	
МСНС	3,166.8	2,515.1	651.7	226.5	66.3	160.2	


* Reference purpose only

**Ajustments for MCHC consolidation


- Those for net slaes represent elimination of internal transcations.

- Those for operating income represent primarily amortization of goodwill as well as elimination of internal transcations.

Trend of Financial Position



Ratio of shareholders' equity to total assets Debt-equity ratio Net Debt-equity ratio



Consolidated Capital Expenditure, Depreciation & Amortization, R&D Expenses, Total Assets, and Number of Employees by Business Segment

		(Billions of yen, unti	l otherwise noted)							
	Capital Expenditure		Depreciation& Amortization				R&D Ex	penses	Total Assets	Number of Employees
	FY2011 Forecast	FY2010 Actual	FY2011 Forecast	FY2010 Actual	FY2011 Forecast	FY2010 Actual	FY2010 Actual	FY2010 Actual		
Electronics Applications	7.0	6.6	9.0	9.0	10.0	9.2	129.3	3,364		
Designed Materials	56.0	34.5	49.0	48.3	24.0	21.8	712.5	13,907		
Health Care	16.0	18.5	19.0	18.9	78.0	73.9	852.7	12,946		
Chemicals	30.0	29.3	34.0	31.1	5.0	5.7	655.9	5,538		
Polymers	32.0	21.9	34.0	34.5	16.0	13.9	744.6	7,426		
Others	3.0	3.2	4.0	3.9	1.0	0.9	296.0	9,704		
Corporate	2.0	3.8	3.0	3.0	6.0	5.4	(97.0)	997		
Total	146.0	117.8	152.0	148.7	140.0	130.8	3,294.0	53,882		

Consolidated Operating Income by Business Segment (1Q and 2Q of FY2011 Forecast)

						(Billions of Ye
	1Q Forecast	2Q Forecast	1H of FY2011 Forecast	1Q Actual	2Q Actual	1H of FY2010 Actual
Total	38.0	43.0	81.0	60.8	50.6	111.4
Electronics Applications	(0.5)	0.5	0.0	2.9	0.3	3.2
Designed Materials	7.5	9.5	17.0	9.9	10.9	20.8
Functional Products (*)	3.0	4.0	7.0	3.5	4.6	8.′
Performance Chemicals (*)	4.5	5.5	10.0	6.4	6.3	12.
Health Care	13.0	14.0	27.0	29.0	15.6	44.6
Pharmaceuticals (*)	12.5	12.5	25.0	27.2	14.9	42.
Diagnostics, Clinical Testing and API (*)	0.5	1.5	2.0	1.8	0.7	2.
Chemicals	13.0	7.0	20.0	12.1	9.8	21.9
Petrochemicals (*)	9.0	3.0	12.0	5.2	3.5	8.
Carbon (*)	4.0	4.0	8.0	6.9	6.3	13.
Polymers	7.5	12.5	20.0	9.4	14.9	24.3
Polyolefins and Advanced Polymers (*)	(2.0)	3.0	1.0	5.2	6.0	11.
MMA Monomers and Polymers (*)	9.5	9.5	19.0	4.2	8.9	13.
Others	(0.5)	1.5	1.0	(0.4)	1.0	0.0
Corporate	(2.0)	(2.0)	(4.0)	(2.1)	(1.9)	(4.0
* Approximation for reference purpose only	-					
mpact of the earthquake	(15.7)	(8.5)	(24.2)	-	-	
Operating income exclud. impact of the earthquake	53.7	51.5	105.2	60.8	50.6	111.4
Operating income exclud. impact of the earthquake and results of	38.2	36.0	74.2	33.6	35.7	69.

"Pharmaceuticals"

26

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

Actual results could differ materially due to numerous factors, including without limitation, marketing conditions and the effects of industry competition.